Under the terms of the agreement, Pfizer shareholders will own 57% of the combined new company, and Mylan shareholders will own 43%. The new company is likely to again change Mylan's global outlook; the transaction will enable the new company to expand Mylan's geographic reach for its existing product portfolio and future pipeline, including investments that have been made across complex generics and biosimilars, into new growth markets where Upjohn has existing sales infrastructure and local market presence. Combined, the two firms will offer over 3,000 brands and molecules to over 60,000 customers globally. Worldwide, it will have 25 oral solid dosage, seven injectable, eight complex dosage form and 11 active pharmaceutical ingredient sites. The new company is expected to have pro forma 2020 revenues of USD19bn to USD20bn. The new company will be domiciled in the US and will operate global centres in Pittsburgh, PA, Shanghai, China, and Hyderabad, India.